Peripheral Arterial Disease Pipeline Drugs Report 2025 By Delveinsight: Exploring Breakthrough Therapies And Advancements Shaping The Global Healthcare Landscape

DelveInsight's "Peripheral Arterial Disease Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Peripheral Arterial Disease pipeline landscape. It covers the Peripheral Arterial Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peripheral Arterial Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Peripheral Arterial Disease Pipeline? Click here to explore the therapies and trials making headlines @ Peripheral Arterial Disease Pipeline Outlook Report

Key Takeaways from the Peripheral Arterial Disease Pipeline Report

• On 09 September 2025, Cell Biopeutics Resources Sdn Bhd announced a study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to peripheral arterial disease.
• DelveInsight's Peripheral Arterial Disease Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Peripheral Arterial Disease treatment.
• The leading Peripheral Arterial Disease Companies such as AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics and others.
• Promising Peripheral Arterial Disease Therapies such as Renexin CR 200/160mg, Aspirin 100mg, Actovegin, Dotarem, Gadovist, Propionyl-L-carnitine Tablets, edoxaban, Clopidogrel, Aspirin and others.

Want to know which companies are leading innovation in Peripheral Arterial Disease? Dive into the full pipeline insights @ Peripheral Arterial Disease Clinical Trials Assessment

The Peripheral Arterial Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Peripheral Arterial Disease Pipeline Report also highlights the unmet needs with respect to the Peripheral Arterial Disease.

Peripheral Arterial Disease Overview

Peripheral Arterial Disease (PAD) is a circulatory condition where narrowed arteries reduce blood flow to the limbs, commonly affecting the legs. It is primarily caused by atherosclerosis, where fatty deposits build up in the artery walls, restricting blood flow. Symptoms include leg pain during walking (claudication), numbness, or non-healing wounds. PAD increases the risk of heart attack, stroke, and can lead to severe complications like limb amputation if untreated. It is a condition characterized by the narrowing or blockage of peripheral arteries, most commonly in the legs, due to atherosclerosis.

Peripheral Arterial Disease Emerging Drugs Profile

• Semaglutide: Novo Nordisk

Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Peripheral Artery Disease.

• ACP 01: Hemostemix

ACP-01 is Hemostemix's lead product, designed as an autologous cell therapy for regenerating damaged tissues in patients with critical limb ischemia (CLI) and other vascular diseases. The treatment uses the patient's own stem cells, specifically angiogenic cell precursors (ACPs), which are harvested, processed, and then re-injected into areas of poor circulation. These ACPs promote the growth of new blood vessels, aiming to restore blood flow and prevent amputations. ACP-01 has received orphan drug designation from the FDA and has shown promise in clinical trials, particularly for patients with no alternative treatment options. Currently, the drug is in the Phase II stage of its development for the treatment of Peripheral Arterial Disease.

• Revacept: AdvanceCor

Revacept is the first Fc-fusion protein to be used as pharmaceutical in stroke and heart attack. With its GPVI component, Revacept binds to damaged blood vessel walls, covers them and thus forms a kind of vascular patch. This prevents the formation of thrombi in the arteries. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Peripheral Artery Disease.

If you're tracking ongoing Peripheral Arterial Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Peripheral Arterial Disease Treatment Drugs

The Peripheral Arterial Disease Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral Arterial Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Arterial Disease Treatment.
• Peripheral Arterial Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peripheral Arterial Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral Arterial Disease market.

Peripheral Arterial Disease Companies

AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics and others.

Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Peripheral Arterial Disease Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Peripheral Arterial Disease Pipeline Report covers it all – check it out now @ Peripheral Arterial Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Peripheral Arterial Disease Pipeline Report

• Coverage- Global
• Peripheral Arterial Disease Companies- AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics and others.

• Promising Peripheral Arterial Disease Therapies- Renexin CR 200/160mg, Aspirin 100mg, Actovegin, Dotarem, Gadovist, Propionyl-L-carnitine Tablets, edoxaban, Clopidogrel, Aspirin and others.

• Peripheral Arterial Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peripheral Arterial Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Peripheral Arterial Disease Treatment landscape in this detailed analysis @ Peripheral Arterial Disease Emerging Drugs and Major Players

Table of Contents